Protocol Search

Central Protocol Notices

NRG Oncology Study Terminations (August 15, 2023)
NRG Oncology Memo on Cisplatin & Carboplatin Shortages (June 16, 2023)
NCI Letter Regarding Coverage of Proton Therapy (August 26, 2020) 
NCI Rare Tumor Letter (March 4, 2020) 

Study Title Status Phase Disease Category Disease Site
NRG-CC012CDManaging Symptoms and Psychological Distress During Oral Anti-Cancer TreatmentOpen to AccrualOtherCancer Care Delivery Research [CD]Other
NRG-GY032A Phase II Study of Tailored Adjuvant Therapy in POLE-Mutated and p53-wildtype/NSMP Early-Stage Endometrial Cancer (RAINBO BLUE & TAPER)

Temporarily Closed to AccrualIIGynecologic [GY]Uterine Corpus
EAY191-N5Molecular Analysis for Combination Therapy Choice (ComboMATCH) EAY191-N5: A Randomized Trial of Neratinib, a Pan-ERBB Inhibitor, Alone or in Combination with Palbociclib, a CDK4/6 Inhibitor, in Patients with HER2+ Gynecologic Cancers and Other Solid Tumors A ComboMATCH Treatment Trial

Open to AccrualIIGynecologic [GY]Multiple
NRG-CC011NRG-CC011: Cognitive Training For Cancer Related Cognitive Impairment in Breast Cancer Survivors: A Multi-Center Randomized Double-Blinded Controlled Trial

Open to AccrualOtherSymptom Management [CC]Other
NRG-GY033A Phase II Study of Androgen Receptor (AR) Inhibition by Darolutamide in combination with Leuprolide Acetate and Exemestane in Recurrent Adult-Type Ovarian Granulosa Cell Tumors
Temporarily Closed to AccrualIIGynecologic [GY]Ovarian
NRG-HN011A Randomized Phase II Study of Nivolumab versus Nivolumab and BMS-986016 (Relatlimab) as Maintenance Treatment after First-line Treatment with Platinum-Gemcitabine-Nivolumab for Patients with Epstein-Barr Virus-Associated Recurrent/Metastatic Nasopharyngeal Carcinoma (REMAIN)Open to AccrualIIHead and Neck [HN]Head and Neck
NRG-GU013The Phase III ‘High Five Trial’ Five Fraction Radiation For High-Risk Prostate CancerOpen to AccrualIIIGenitourinary [GU]Prostate
NRGF-001Activity Monitoring To Improve Patient Care During Chemoradiotherapy For Locally Advanced Non-small Cell Lung Cancer (La-nsclc)

Open to AccrualILung [LU]Non-small Cell Lung Cancer
NRG-BR009A Phase III Adjuvant Trial Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression plus Endocrine Therapy in Premenopausal Patients with pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score ≤ 25 (OFSET)Open to AccrualIIIBreast [BR]Breast
NRG-GY031A Phase IB Study Of Combination Atr (M1774) And Bet Inhibition (Zen003694) To Exploit Arid1a Loss In Recurrent Ovarian And Endometrial Cancer

Open to AccrualI/IIGynecologic [GY]Uterine Corpus
NRG-LU008Phase III Prospective Randomized Trial of Primary Lung Tumor Stereotactic Body Radiation Therapy Followed by Concurrent Mediastinal Chemoradiation for Locally Advanced Non-Small Cell Lung CancerOpen to AccrualIIILung [LU]Non-small Cell Lung Cancer
NRG-BR008NRG-BR008: A Phase III Randomized Trial of Radiotherapy Optimization for Low-Risk HER2-Positive Breast Cancer (HERO)Open to AccrualIIIBreast [BR]Breast
EAY191-N2EAY191-N2: Phase 2 Trial of Fulvestrant and Binimetinib in Patients With Hormone Receptor-Positive Metastatic Breast Cancer With a Frameshift or Nonsense Mutation or Genomic Deletion in NF1

Open to AccrualIIBreast [BR]Breast
EAY191-N4 Molecular Analysis for Combination Therapy Choice (ComboMATCH) EAY191-N4: A Randomized Trial of Selumetinib and Olaparib or Selumetinib Alone in Patients with Recurrent or Persistent RAS Pathway Mutant Ovarian and Endometrial Cancers - A ComboMATCH Treatment Trial

Open to AccrualIIGynecologic [GY]Multiple
NRG-GY028A Phase IB and Randomized Phase II trial of Megestrol Acetate with or without Ipatasertib in Recurrent or Metastatic Endometrioid Endometrial Cancer

Open to AccrualI/IIGynecologic [GY]Uterine Corpus
NRG-HN010A Controlled, Randomized Phase II Trial of Docetaxel Plus Trastuzumab Versus Ado-Trastuzumab Emtansine for Recurrent, Metastatic, or Treatment-Naïve, Unresectable Her2-Positive Salivary Gland CancerOpen to AccrualIIHead and Neck [HN]Head and Neck
NRG-CC010A Phase III Trial of the Impact of Sentinel Lymph Node Mapping On Patient Reported Lower Extremity Limb Dysfunction in Endometrial Cancer

Open to AccrualIIIGynecologic [GY]Uterine Corpus
NRG-BN012A Randomized Phase III Trial Of Pre-Operative Compared To Post-Operative Stereotactic Radiosurgery In Patients With Resectable Brain MetastasesOpen to AccrualIIIBrain [BN]Brain Mets
NRG-GY026A Phase II/III Study Of Paclitaxel/Carboplatin Alone Or Combined With Either Trastuzumab And Hyaluronidase-Oysk (Herceptin Hylecta) Or Pertuzumab, Trastuzumab, And Hyaluronidase-Zzxf (Phesgo) In Her2 Positive, Stage I-Iv Endometrial Serous Carcinoma Or Carcinosarcoma

Open to AccrualII/IIIGynecologic [GY]Uterine Corpus
NRG-GY029A Randomized Phase II trial comparing the combination of PI3K inhibitor Copanlisib (BAY 80-6946) and PARP inhibitor Olaparib (AZD2281) to standard chemotherapy in patients with recurrent platinum resistant ovarian, fallopian tube, or primary peritoneal cancer who have progressed through prior PARP inhibitor therapy

Closed to AccrualIIGynecologic [GY]Ovarian

Open to AccrualIGynecologic [GY]Ovarian
NRG-GU012Randomized Phase II Stereotactic Ablative Radiation Therapy (SABR) For Metastatic Unresected Renal Cell Carcinoma (RCC) Receiving Immunotherapy (Samurai)Open to AccrualIIGenitourinary [GU]Other
NRG-GI008Colon Adjuvant Chemotherapy based on Evaluation of Residual Disease (CIRCULATE-NORTH AMERICA)Open to AccrualII/IIIGastrointestinal [GI]Colorectal

Open to AccrualIIGynecologic [GY]Uterine Corpus
NRG-GU011A Phase II Double-Blinded, Placebo Controlled Trial of Prostate Oligometastatic Radiotherapy with or without Androgen Deprivation Therapy in Oligometastatic Prostate Cancer (NRG Promethean)Open to AccrualIIGenitourinary [GU]Prostate
NRG-BN011A Phase III Trial of Lomustine-Temozolomide Combination Therapy Versus Standard Temozolomide in Patients with Methylated MGMT Promoter GlioblastomaOpen to AccrualIIIBrain [BN]Malignant Glioma
NRG-HN009Randomized Phase II/III Trial of Radiation with High-Dose Cisplatin (100 mg/m2) Every Three Weeks versus Radiation with Low-Dose Weekly Cisplatin (40 mg/m2) for Patients with Locoregionally Advanced Squamous Cell Carcinoma of The Head And Neck (SCCHN)Open to AccrualII/IIIHead and Neck [HN]Head and Neck
NRG-CC005Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous PolypsOpen to AccrualIIIPrevention [CC]Colorectal
NRG-GU010Parallel Phase III Randomized Trials Of Genomic-Risk Stratified Unfavorable Intermediate Risk Prostate Cancer: De-Intensification And Intensification Clinical Trial Evaluation (Guidance)Open to AccrualIIIGenitourinary [GU]Prostate
NRG-GY024Groningen International Study on Sentinel Nodes in Vulvar Cancer (GROINSS-V) III: A Prospective Phase II Treatment TrialOpen to AccrualIIGynecologic [GY]Cervix
NRG-BN010A Safety Run-In and Phase II Study Evaluating the Efficacy, Safety, and Impact on the Tumor Microenvironment of the Combination of Tocilizumab, Atezolizumab, and Fractionated Stereotactic Radiotherapy in Recurrent Glioblastoma Open to AccrualI/IIBrain [BN]Other
NRG-BR007A Phase III Clinical Trial evaluating De-escalation of Breast Radiation for Conservative Treatment of Stage I, Hormone Sensitive, HER2-Negative, Oncotype Recurrence Score Less than or Equal to 18: The DEBRA TrialOpen to AccrualIIIBreast [BR]Breast
NRG-GY023A Randomized Phase II Trial of Triplet Therapy (A PD-L1 Inhibitor Durvalumab (MEDI4736) in Combination With Olaparib and Cediranib) Compared to Olaparib and Cediranib or Durvalumab (MEDI4736) and Cediranib or Standard of Care Chemotherapy in Women With Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Primary Peritoneal or Fallopian Cancer Who Have Received Prior BevacizumabClosed to AccrualIIGynecologic [GY]Ovarian
GOG-0268A Phase II Evaluation of Temsirolimus (CCI-779) (NCI Supplied Agent: 683864, IND #61010) in Combination with Carboplatin and Paclitaxel followed by Temsirolimus Consolidation as First-line Therapy in the Treatment of Clear Cell Carcinoma of the Ovary.Closed to AccrualIIGynecologic [GY]Ovarian
NRG-CC009Phase III Trial of Stereotactic Radiosurgery (SRS) versus Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) for 10 or Fewer Brain Metastases from Small Cell Lung CancerOpen to AccrualIIISymptom Management [CC]Other
GOG-0214Phase II Double Blind Randomized Trial Evaluating the Biologic Effect of Levonorgestrel on the Ovarian Epithelium in Women at High Risk for Ovarian Cancer (IND# 79,610)

TerminatedIIGynecologic [GY]Ovarian
GOG-0207A Randomized Double-Blind Phase II Trial of Celecoxib, A COX-2 Inhibitor, In The Treatment of Patients With Cervical Intraepithelial Neoplasia 2/3 or 3TerminatedIIGynecologic [GY]Cervix
GOG-0199Prospective Study of Risk-Reducing Salpingo-Oophorectomy and Longitudinal CA-125 Screening Among Women at Increased Genetic Risk of Ovarian Cancer
TerminatedIGynecologic [GY]Ovarian
NRG-BN009Phase III Trial of Stereotactic Radiosurgery (SRS) or Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) for Distant Brain Relapse With Brain Metastasis Velocity ≥4 Brain Metastases/Year

Open to AccrualIIIBrain [BN]Other
NRG-HN008Phase I Trial With Expansion Cohort of DNA-PK Inhibition and IMRT In Cisplatin-Ineligible Patients with Stage 3-4 Local-Regionally Advanced Head and Neck Squamous Cell Carcinoma (HNSCC)Open to AccrualIHead and Neck [HN]Head and Neck
NRG-GU009Parallel Phase III Randomized Trials For High Risk Prostate Cancer Evaluating De-Intensification For Lower Genomic Risk and Intensification of Concurrent Therapy for Higher Genomic Risk with Radiation (Predict-RT*) *Prostate RNA Expression/Decipher To Individualize Concurrent Therapy with RadiationOpen to AccrualIIIGenitourinary [GU]Prostate
NRG-HN007An Open Label, Phase III Study of Platinum-Gemcitabine With or Without Nivolumab in the First-Line Treatment of Recurrent or Metastatic Nasopharyngeal CarcinomaTerminatedIIIHead and Neck [HN]Head and Neck
EA8185ECOG-ACRIN/NRG Joint Study:A Study of Chemotherapy and Radiation Therapy Compared to Chemotherapy and Radiation Therapy Plus MEDI4736 (Durvalumab) Immunotherapy for Bladder Cancer Which Has Spread to the Lymph Nodes, the INSPIRE StudyClosed to AccrualIIGenitourinary [GU]Bladder
NRG-LU007RAndomized Phase II/III Trial of Consolidation Radiation + Immunotherapy for ES-SCLC: RAPTOR TrialOpen to AccrualII/IIILung [LU]Small Cell
GOG-0210A Molecular Staging Study of Endometrial CarcinomaTerminatedIGynecologic [GY]Uterine Corpus
NRG-BN007A Randomized Phase II/III Open-Label Study of Ipilimumab and Nivolumab Versus Temozolomide In Patients With Newly Diagnosed MGMT (Tumor O-6-Methylguanine DNA Methyltransferase) Unmethylated GlioblastomaClosed to AccrualII/IIIBrain [BN]Malignant Glioma
NRG-CC008A Non-Randomized Prospective Clinical Trial Comparing the Non-Inferiority of Salpingectomy to Salpingo-Oophorectomy to Reduce the Risk of Ovarian Cancer Among BRCA1 Carriers [SOROCk]Open to AccrualOtherPrevention [CC]Ovarian
NRG-HN006Randomized Phase II/III Trial Of Sentinel Lymph Node Biopsy Versus Elective Neck Dissection For Early-Stage Oral Cavity CancerOpen to AccrualII/IIIHead and Neck [HN]Head and Neck
NRG-GI007Phase I Trial with Expansion Cohort of OBP-301 (Telomelysin) and Definitive Chemoradiation for Patients with Locally Advanced Esophageal And Gastroesophageal Adenocarcinoma Who are Not Candidates for SurgeryOpen to AccrualIGastrointestinal [GI]Esophageal
S1914SWOG/NRG Joint Study: A Randomized Phase III Trial of Induction/ Consolidation Atezolizumab (NSC #783608) + SBRT Versus SBRT Alone in High Risk, Early Stage NSCLCOpen to AccrualIIILung [LU]Non-small Cell Lung Cancer
S1806SWOG/NRG Joint Study: Phase III Randomized Trial of Concurrent Chemoradiotherapy with or without Atezolizumab in Localized Muscle Invasive Bladder Cancer Closed to AccrualIIIGenitourinary [GU]Bladder
NRG-GU008Randomized Phase III Trial Incorporating Apalutamide and Advanced Imaging into Salvage Treatment for Patients with Node-Positive Prostate Cancer After Radical Prostatectomy (INNOVATE*) *INtensifying treatment for NOde positive prostate cancer by VArying the hormonal ThErapyOpen to AccrualIIIGenitourinary [GU]Prostate
NRG-GY020A Phase III Randomized Trial of Radiation +/- Pembrolizumab (MK-3475) for Newly Diagnosed, Early Stage High Intermediate Risk Mismatch Repair Deficient (dMMR) Endometrioid Endometrial CancerClosed to AccrualIIIGynecologic [GY]Uterine Corpus
NRG-LU006Phase III Randomized Trial of Pleurectomy/Decortication Plus Chemotherapy With or Without Adjuvant Hemithoracic Intensity-Modulated Pleural Radiation Therapy (IMPRINT) For Malignant Pleural Mesothelioma (MPM)TerminatedIIILung [LU]Mesothelioma
NRG-GI005Phase II/III Study of Circulating tumOr DNA as a Predictive BiomaRker in Adjuvant Chemotherapy in Patients with Stage IIA
Colon Cancer (COBRA)
Closed to AccrualII/IIIGastrointestinal [GI]Colorectal
NRG-GY021A Phase II Randomized Trial of Olaparib versus Olaparib plus Tremelimumab in Platinum-Sensitive Recurrent Ovarian CancerClosed to AccrualIIGynecologic [GY]Ovarian
NRG-GY022Assessment of Carboplatin Clearance Predictors: A PK Study on NCI-sponsored Clinical Trials or Standard of Care Treatments Using CarboplatinOpen to AccrualIGynecologic [GY]Other
NRG-GY019A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients with Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or PeritoneumOpen to AccrualIIIGynecologic [GY]Ovarian
GOG-0274 RTOG 1174A Phase III trial of adjuvant chemotherapy following chemoradiation as primary treatment for locally advanced cervical cancer compared to chemoradiation alone: THE OUTBACK TRIALClosed to AccrualIIIGynecologic [GY]Cervix
NRG-GY014A Phase II Study of Tazemetostat (EPZ-6438) (IND # 138671) in Recurrent or Persistent Endometrioid or Clear Cell Carcinoma of the Ovary, and Recurrent or Persistent Endometrioid Endometrial AdenocarcinomaClosed to AccrualIIGynecologic [GY]Ovarian
NRG-GU006A Phase II, Double-Blinded, Placebo-Controlled Randomized Trial of Salvage Radiotherapy with or without Enhanced Anti-Androgen Therapy with Apalutamide in Recurrent Prostate CancerClosed to AccrualIIGenitourinary [GU]Prostate
GOG-0237Comparative Analysis of CA-IX, p16, Proliferative Markers, and Human Papilloma Virus (HPV) in the Diagnosis of Significant Cervical Lesions in Patients with a Cytologic Diagnosis of Atypical Glandular Cells (AGC)Closed to AccrualIGynecologic [GY]Cervix
GOG-0238A Randomized Trial of Pelvic Irradiation with or without Concurrent Weekly Cisplatin in Patients with Pelvic-only Recurrence of Carcinoma of the Uterine CorpusClosed to AccrualIIGynecologic [GY]Uterine Corpus
NRG-GY012A Randomized Phase II Study Comparing Single-Agent Olaparib, Single Agent Cediranib, and the Combinations of Cediranib/Olaparib, Olaparib/Durvalumab (MEDI4736), Cediranib/Durvalumab (MEDI4736), Olaparib/AZD5363 (Capivasertib) in Women with Recurrent, Persistent or Metastatic Endometrial Cancer.: A Platform Trial for Women with Recurrent or Persistent Endometrial CancerClosed to AccrualIIGynecologic [GY]Uterine Corpus
NRG-GU007Randomized Phase II Trial of Niraparib With Standard Combination Radiotherapy and Androgen Deprivation Therapy (ADT) in High Risk Prostate Cancer (With Initial Phase I)Temporarily Closed to AccrualI/IIGenitourinary [GU]Prostate
RTOG-1112Randomized Phase III Study of Sorafenib versus Stereotactic Body Radiation Therapy followed by Sorafenib in Hepatocellular CarcinomaClosed to AccrualIIIGastrointestinal [GI]Liver
NRG-HN005A Randomized Phase II/III Trial of De-Intensified Radiation Therapy for Patients with Early-Stage, p16-Positive, Non-Smoking Associated Oropharyngeal CancerTemporarily Closed to AccrualII/IIIHead and Neck [HN]Head and Neck
NRG-LU003A Biomarker-Driven Protocol for Previously Treated ALK-Positive Non-Squamous NSCLC Patients: The NCI-NRG ALK Master Protocol  Closed to AccrualIILung [LU]Non-small Cell Lung Cancer
NRG-CC004Phase II Double Blind Dose Finding Trial of Bupropion Versus Placebo For Sexual Desire in Women With Breast or Gynecologic CancerTerminatedIISymptom Management [CC]Other
NRG-DT001A Phase Ib Trial of Neoadjuvant AMG-232 Concurrent with Preoperative Radiotherapy in Wild-Type P53 Soft Tissue Sarcoma (STS)Closed to Accrual & TreatmentIOther [DT]Sarcoma
RTOG-0924Androgen Deprivation Therapy and High Dose Radiotherapy With or Without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer: A Phase III Randomized TrialClosed to AccrualIIIGenitourinary [GU]Prostate
NRG-LU005Limited Stage Small Cell Lung Cancer (LS-SCLC):  A Phase III Randomized Study of Chemoradiation Versus Chemoradiation Plus AtezolizumabClosed to AccrualIIILung [LU]Small Cell
NRG-LU002Maintenance Systemic Therapy Versus Local Consolidative Therapy (LCT) Plus Maintenance Systemic Therapy For Limited Metastatic Non-Small Cell Lung Cancer (NSCLC):  A Randomized Phase II/III TrialClosed to AccrualII/IIILung [LU]Non-small Cell Lung Cancer
NRG-GY007A Phase I/II Study of Ruxolitinib with Front-Line Neoadjuvant and Post-Surgical Therapy in Patients with Advanced Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal CancerClosed to AccrualI/IIGynecologic [GY]Ovarian
NRG-GU003A Randomized Phase III Trial Of Hypofractionated Post-Prostatectomy Radiation Therapy (HYPORT) Versus Conventional Post-Prostatectomy Radiation Therapy (COPORT)Closed to AccrualIIIGenitourinary [GU]Prostate
NRG-BR005A Phase II Trial Assessing the Accuracy of Tumor Bed Biopsies in Predicting Pathologic Response in Patients with Clinical/Radiologic Complete Response after Neoadjuvant Chemotherapy in Order to Explore the Feasibility of Breast Conserving Treatment without SurgeryCompleteIIBreast [BR]Breast
NRG-CC003A Randomized Phase II/III Trial of Prophylactic Cranial Irradiation with or without Hippocampal Avoidance for Small Cell Lung CancerClosed to AccrualII/IIISymptom Management [CC]Other
GOG-9923A Phase I Study of Carboplatin/Paclitaxel/CTEP-Supplied Bevacizumab(NSC #704865, IND #7921)and CTEP-Supplied Agent ABT-888(NSC #737664,IND# 77840)in Newly Diagnosed Patients with Previously Untreated Epithelial Ovarian, Fallopian Tube or Primary PeritCancerTerminatedIGynecologic [GY]Ovarian
NSABP B-55 BIG 6-13OlympiA: A Randomised, Double-Blind, Parallel Group, Placebo-Controlled Multi-Centre Phase III Study to Assess the Efficacy and Safety of Olaparib Versus Placebo as Adjuvant Treatment in Patients with Germline BRCA1/2 Mutations and High Risk HER2 Negative Primary Breast Cancer Who Have Completed Definitive Local Treatment and Neoadjuvant or Adjuvant ChemotherapyClosed to Accrual & TreatmentIIIBreast [BR]Breast
GOG-0277A phase III randomized trial of gemcitabine (nsc# 613327) plus docetaxel (nsc#  628503) followed by doxorubicin (nsc# 123127) versus observation for uterus-limited, high-grade uterine leiomyosarcomaTerminatedIIIGynecologic [GY]Uterine Corpus
GOG-0260A Phase II Evaluation of Elesclomol Sodium and Weekly Paclitaxel in the Treatment of Recurrent or Persistent Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer (IND 110072) (NCT# 00888615).TerminatedIIGynecologic [GY]Ovarian
GOG-0186KA Randomized Phase II Study of NCI Supplied Cabozantinib (NSC #761968 IND #116059) versus weekly paclitaxel (NSC #673089) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal CancerTerminatedIIGynecologic [GY]Ovarian
RTOG-0534A Phase III Trial of Short Term Androgen Deprivation With Pelvic Lymph Node or Prostate Bed Only Radiotherapy (SPPORT) in Prostate Cancer Patients With a Rising PSA After Radical ProstatectomyClosed to AccrualIIIGenitourinary [GU]Prostate
RTOG-1119Phase II Randomized Study of Whole Brain Radiotherapy/Stereotactic Radiosurgery in Combination With Concurrent Lapatinib in Patients With Brain Metastasis From HER2-Positive Breast Cancer: A Collaborative Study of RTOG and KROGTerminatedIIBreast [BR]Breast
NSABP B-31A Randomized Trial Comparing The Safety And Efficacy Of Adriamycin And Cyclophosphamide Followed By Taxol (AC?T) To That Of Adriamycin And Cyclophosphamide Followed By Taxol Plus Herceptin (AC?T + H) In Node-Positive Breast Cancer Patients Who Have Tumors That Overexpress HER2TerminatedIIIBreast [BR]Breast
NRG-GY016A Phase II Study of MK-3475 (Pembrolizumab) (NSC #776864) + Epacadostat (NSC #766086) in Recurrent Clear Cell Carcinoma of the OvaryClosed to AccrualIIGynecologic [GY]Ovarian
GOG-9926A Phase I Evaluation of Extended Field Radiation Therapy with Concomitant Cisplatin Chemotherapy Followed by Paclitaxel and Carboplatin Chemotherapy in Women with Cervical Carcinoma Metastatic to Para-Aortic Lymph NodesTerminatedIGynecologic [GY]Cervix
NRG-GY001A Phase II Trial of Cabozantinib (XL-184) (NSC #761968) in Women with Recurrent, Clear Cell Carcinoma of the Ovary, Fallopian Tube, or PeritoneumTerminatedIIGynecologic [GY]Ovarian
NRG-LU004Phase I Trial of Radiotherapy Combined With Durvalumab Alone Plus Either Monalizumab or Oleclumab in PD-L1 High Locally Advanced Non-Small Cell Lung Cancer (NSCLC) (ARCHON-1) Open to AccrualILung [LU]Non-small Cell Lung Cancer
RTOG-0815A Phase III Prospective Randomized Trial of Dose-Escalated Radiotherapy with or without Short-Term Androgen Deprivation Therapy for Patients with Intermediate-Risk Prostate CancerClosed to AccrualIIIGenitourinary [GU]Prostate
NRG-CC007CDIncreasing the Dose of Survivorship Care Planning in Prostate Cancer Survivors Who Receive Androgen Deprivation TherapyClosed to AccrualIICancer Care Delivery Research [CD]Other
NRG-HN004Randomized Phase II/III Trial of Radiotherapy with Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy with Concurrent Cetuximab in Patients with Locoregionally Advanced Head and Neck Cancer with a Contraindication to CisplatinClosed to Accrual & TreatmentII/IIIHead and Neck [HN]Head and Neck
COG-NRG ARST1321Pazopanib Neoadjuvant Trial in Non-Rhabdomyosarcoma Soft Tissue Sarcomas (PAZNTIS):  A Phase II/III Randomized Trial of Preoperative Chemoradiation or Preoperative Radiation Plus or Minus Pazopanib (NSC#737754; IND#118613)Closed to AccrualII/IIIOther [DT]Sarcoma
NRG-BR004A Randomized, Double-Blind, Phase III Trial of Taxane/Trastuzumab/Pertuzumab with Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast CancerClosed to AccrualIIIBreast [BR]Breast
GOG-0213A Phase III Randomized Controlled Clinical Trial Of Carboplatin and Paclitaxel or  Gemcitabine) Alone or in Combination with Bevacizumab (NSC #704865, IND #113912) Followed by Bevacizumab and Secondary Cytoreductive Surgery in Platinum-Sensitive, Recurrenovarian, Peritoneal Primary and Fallopian Tube Cancer. NCI-Supplied Agents: Bevacizumab (NSC #704865, IND #113912) Closed to AccrualIIIGynecologic [GY]Ovarian
NRG-GI006Phase III Randomized Trial of Proton Beam Therapy (PBT) Versus Intensity Modulated Photon Radiotherapy (IMRT) for the Treatment of Esophageal CancerOpen to AccrualIIIGastrointestinal [GI]Esophageal
RTOG-0926A Phase II Protocol for Patients with Stage T1 Bladder Cancer to Evaluate Selective Bladder Preserving Treatment by Radiation Therapy Concurrent with Radiosensitizing Chemotherapy Following a Thorough Transurethral Surgical Re-StagingTerminatedIIGenitourinary [GU]Bladder
NSABP B-39 RTOG 0413A Randomized Phase III Study of Conventional Whole Breast Irradiation (WBI) Versus Partial Breast Irradiation (PBI) for Women with Stage 0, I, or II Breast CancerCompleteIIIBreast [BR]Breast
NSABP B-40A Randomized Phase III Trial of Neoadjuvant Therapy in Patients with Palpable and Operable Breast Cancer Evaluating the Effect on Pathologic Complete Response (pCR) of Adding Capecitabine or Gemcitabine to Docetaxel when Administered Before AC with or without Bevacizumab and Correlative Science Studies Attempting to Identify Predictors of High Likelihood for pCR with Each of the RegimensCompleteIIIBreast [BR]Breast
NRG-GY006A Randomized Phase III Trial of Radiation Therapy and Cisplatin Alone or in Combination with Intravenous Triapine in Women with Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal CancerClosed to AccrualIIIGynecologic [GY]Cervix
NRG-GY005A Randomized Phase II/III study of the combination of Cediranib and Olaparib compared to Cediranib or Olaparib alone, or Standard of care chemotherapy in women with recurrent platinum-resistant or -refractory ovarian, fallopian tube, or primary peritoneal cancer (COCOS).Closed to AccrualII/IIIGynecologic [GY]Ovarian
NRG-GY004A Phase III Study Comparing Single-Agent Olaparib or the Combination of Cediranib and Olaparib to Standard Platinum-Based Chemotherapy in Women with Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal CancerClosed to AccrualIIIGynecologic [GY]Ovarian
GOG-0239A Phase II Trial of AZD6244 (NSC #748727, IND #77782) in Women with Recurrent Low-Grade Serous Carcinoma of the Ovary or PeritoneumTerminatedIIGynecologic [GY]Ovarian
NRG-BN002Phase I Study of Ipilimumab, Nivolumab, and the Combination in Patients With Newly Diagnosed GlioblastomaTerminatedIBrain [BN]Malignant Glioma
NRG-GU005Phase III IGRT and SBRT versus IGRT and Hypofractionated IMRT for Localized Intermediate Risk Prostate CancerClosed to AccrualIIIGenitourinary [GU]Prostate
NRG-LU001Randomized Phase II Trial of Concurrent Chemoradiotherapy +/- Metformin HCL in Locally Advanced NSCLCClosed to AccrualIILung [LU]Non-small Cell Lung Cancer
RTOG-1106RTOG 1106/ACRIN 6697, Randomized Phase II Trial of Individualized Adaptive Radiotherapy Using During-Treatment FDG-PET/CT and Modern Technology in Locally Advanced Non-Small Cell Lung Cancer (NSCLC)TerminatedIILung [LU]Non-small Cell Lung Cancer
NRG-HN001Randomized Phase II and Phase III Studies of Individualized Treatment for Nasopharyngeal Carcinoma Based on Biomarker Epstein Barr Virus (EBV) Deoxyribonucleic Acid (DNA)Closed to AccrualII/IIIHead and Neck [HN]Head and Neck
GOG-0278Evaluation of Physical Function and Quality of Life (QOL) Before and After Non-Radical Surgical Therapy (Extra Fascial Hysterectomy or Cone Biopsy with Pelvic Lymphadenectomy) for Stage IA1 (LVSI+) and IA2-IB1 (</= 2 cm) Cervical CancerClosed to AccrualI/IIGynecologic [GY]Cervix
RTOG-1122Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or GliosarcomaTerminatedIIBrain [BN]Other
NRG-GY017Anti PD-L1 (Atezolizumab) as an Immune Primer and Concurrently with Extended Field Chemoradiotherapy for Node Positive Locally Advanced Cervical CancerClosed to AccrualIGynecologic [GY]Cervix
RTOG-1308Phase III Randomized Trial Comparing Overall Survival After Photon Versus Proton Chemoradiotherapy for Inoperable Stage II-IIIB NSCLCClosed to AccrualIIILung [LU]Non-small Cell Lung Cancer
NRG-GI003A Phase III Randomized Trial of Protons Versus Photons for Hepatocellular CarcinomaOpen to AccrualIIIGastrointestinal [GI]Liver
NRG-BN003Phase III Trial of Observation Versus Irradiation for a Gross Totally Resected Grade II MeningiomaOpen to AccrualIIIBrain [BN]Benign Brain Tumors
NRG-BN005A Phase II Randomized Trial of Proton vs. Photon Therapy (IMRT) for Cognitive Preservation in Patients with IDH Mutant, Low to Intermediate Grade Gliomas.Closed to AccrualIIBrain [BN]Lower Grade Glioma
NRG-HN003A Phase I and Expansion Cohort Study of Adjuvant Cisplatin, Intensity-Modulated Radiotherapy, and MK-3475 (Pembrolizumab) in High-Risk Head and Neck Squamous Cell Carcinoma (HNSCC)TerminatedIHead and Neck [HN]Head and Neck
RTOG-0233A Phase II Randomized Trial for Patients With Muscle-Invading Bladder Cancer Evaluating Transurethral Surgery and BID Irradiation Plus Either Paclitaxel and Cisplatin or 5-Fluorouracil and Cisplatin Followed by Selective Bladder Preservation and GemcitabiTerminatedIIGenitourinary [GU]Bladder
NRG-GY003A Phase II Randomized Trial of Nivolumab with or without Ipilimumab in Patients with Persistent or Recurrent Epithelial Ovarian, Primary Peritoneal or Fallopian Tube CancerClosed to AccrualIIGynecologic [GY]Ovarian
NRG-GI002A Phase II Clinical Trial Platform of Sensitization Utilizing Total Neoadjuvant Therapy (TNT) in Rectal CancerClosed to AccrualIIGastrointestinal [GI]Anal Canal
AGCT1531A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell TumorsOpen to AccrualIIIGynecologic [GY]Other
NRG-GY008A Phase II Evaluation of Copanlisib BAY 80-6946 IND #130822, A Selective Inhibitor of PI3KCA, in patients with Persistent or Recurrent Endometrial Carcinoma Harboring PIK3CA Hotspot MutationsTerminatedIIGynecologic [GY]Uterine Corpus
RTOG-0627Phase II Trial of Dasatinib in Patients with Recurrent Glioblastoma MultiformeTerminatedIIBrain [BN]Other
NRG-GY002A Phase II Evaluation of Nivolumab, a Fully Human Antibody against PD-1, in the Treatment of Persistent or Recurrent Cervical CancerTerminatedIIGynecologic [GY]Cervix
NRG-BR002A Phase IIR/III Trial of Standard of Care Therapy with or without Stereotactic Body Radiotherapy (SBRT) and/or Surgical Ablation for Newly Oligometastatic Breast CancerClosed to AccrualII/IIIBreast [BR]Breast
RTOG-1114Phase II Randomized Study of Rituximab, Methotrexate, Procarbazine, Vincristine, and Cytarabine With and Without Low-Dose Whole-Brain Radiotherapy for Primary Central Nervous System LymphomaTerminatedIIBrain [BN]Other
GOG-0225Can Diet and Physical Activity Modulate Ovarian or Primary Peritoneal Cancer Progression-Free Survival?Closed to AccrualIIIGynecologic [GY]Ovarian
NRG-GY009A Randomized, Phase II/III Study of Pegylated Liposomal Doxorubicin and CTEP-Supplied Atezolizumab (IND #134427) Versus Pegylated Liposomal Doxorubicin, CTEP-Supplied Bevacizumab and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin and CTEP-Supplied Bevacizumab in Platinum Resistant Ovarian Cancer Closed to AccrualII/IIIGynecologic [GY]Ovarian
NSABP BP-59Bone Marrow Analysis in Early-Stage Breast CancerTerminatedIIIBreast [BR]Breast
NSABP B-37 IBCSG 27-02A Randomized Clinical Trial of Adjuvant Chemotherapy for Radically Resected Loco-Regional Relapse of Breast CancerClosed to Accrual & TreatmentIIIBreast [BR]Breast
RTOG-0522A Randomized Phase III Trial of Concurrent Accelerated Radiation and Cisplatin versus Concurrent Accelerated Radiation, Cisplatin, and Cetuximab C225 [Followed by Surgery for Selected Patients] for Stage III and IV Head and Neck CarcinomasTerminatedIIIHead and Neck [HN]Head and Neck
RTOG-9601A Phase III Trial of Radiation Therapy with or without Casodex in Patients with PSA Elevation Following Radical Prostatectomy for pT3N0 Carcinoma of the ProstateTerminatedIIIGenitourinary [GU]Prostate
RTOG-0232A Phase III Study Comparing Combined External Beam Radiation And Transperineal Interstitial Permanent Brachytherapy With Brachytherapy Alone For Selected Patients With Intermediate Risk Prostatic CarcinomaTerminatedIIIGenitourinary [GU]Prostate
RTOG-0828Pilot Project to Reduce Missing RTOG Quality of Life Data Via Electronic Web-Based Form Collection: A Companion Study for RTOG 0415 (A Phase III Randomized Study of Hypofractionated 3D-CRT/IMRT Versus Conventionally Fractionated 3D-CRT/IMRT in Patients wiClosed to AccrualIIIGenitourinary [GU]Prostate
GOG-0186HA Randomized Phase II Evaluation of Weekly Paclitaxel (NSC# 673089) versus Weekly Paclitaxel with Oncolytic Reovirus (Reolysin NSC # 729968, BB-IND #13370) in the Treatment of Recurrent or Persistent Ovarian, Fallopian Tube or Primary Peritoneal CancerTerminatedIIGynecologic [GY]Ovarian
RTOG-1115Phase III Trial of Dose Escalated Radiation Therapy and Standard Androgen Deprivation Therapy (ADT) with a GnRH Agonist vs. Dose Escalated Radiation Therapy and Enhanced ADT with a GnRH Agonist and TAK-700 for Men with High Risk Prostate CancerClosed to AccrualIIIGenitourinary [GU]Prostate
RTOG-0834Phase III Trial on Concurrent and Adjuvant Temozolomide Chemotherapy in Non-1p/19q Deleted Anaplastic Glioma: The CATNON Intergroup TrialClosed to AccrualIIIBrain [BN]Benign Brain Tumors
NRG-GI001Randomized Phase III Study of Focal Radiation Therapy for Unresectable, Localized Intrahepatic CholangiocarcinomaTerminatedIIIGastrointestinal [GI]Liver
RTOG-9110NCCTG 86-72-51: A Phase III Evaluation of Postoperative Radiation in Low Grade Intracranial Astrocytomas and OligodendrogliomasClosed to AccrualIIIBrain [BN]Other
RTOG-0621Adjuvant 3DCRT/IMRT in Combination with Androgen Suppression and Docetaxel for High Risk Prostate Cancer Patients Post-Prostatectomy: A Phase II TrialTerminatedIIGenitourinary [GU]Other
RTOG-9408A Phase III Trial of the Study of Endocrine Therapy used as a Cytoreductive and Cytostatic Agent Prior to Radiation Therapy in Good Prognosis Locally Confined Adenocarcinoma of the ProstateTerminatedIIIGenitourinary [GU]Prostate
RTOG-0630A Phase II Trial of Image Guided Preoperative Radiotherapy for Primary Soft Tissue Sarcomas of the ExtremityTerminatedIIOther [DT]Sarcoma
RTOG-1203A Randomized Phase III Study Of Standard Vs. IMRT Pelvic Radiation For Post-Operative Treatment Of Endometrial And Cervical Cancer (TIME-C)--RTOG CCOP StudyTerminatedIIIGynecologic [GY]Other
RTOG-0129A Phase III Trial of Concurrent Radiation and Chemotherapy (Followed by Surgery for Residual Primary/N2-3 Nodal Disease) for Advanced Head and Neck CarcinomasTerminatedIIIHead and Neck [HN]Head and Neck
RTOG-1306A Randomized Phase II Study of Individualized Combined Modality Therapy for Stage III Non-Small Cell Lung Cancer (NSCLC)TerminatedIILung [LU]Non-small Cell Lung Cancer
RTOG-0848A Phase IIR and a Phase III Trial Evaluating Both Erlotinib (Ph IIR) And Chemoradiation (Ph III) As Adjuvant Treatment For Patients With Resected Head Of Pancreas AdenocarcinomaClosed to AccrualII/IIIGastrointestinal [GI]Pancreas
RTOG-9402Phase III Intergroup Randomized Comparison of Radiation Alone Vs Pre-Radiation Chemotherapy for Pure and Mixed Anaplastic OligodendrogliomasTerminatedIIIBrain [BN]Other
RTOG-0915A Randomized Phase II Study Comparing 2 Stereotactic Body Radiation Therapy (SBRT) Schedules for Medically Inoperable Patients with Stage I Peripheral Non-Small Cell Lung CancerTerminatedIILung [LU]Non-small Cell Lung Cancer
RTOG-0618A Phase II Trial of Stereotactic Body Radiation Therapy (SBRT) in the Treatment of Patients with Operable Stage I/II Non-Small Cell Lung CancerTerminatedIILung [LU]Non-small Cell Lung Cancer
RTOG-0615A Phase II Study of Concurrent Chemoradiotherapy Using Three-Dimensional Conformal Radiotherapy (3D-CRT) or Intensity-Modulated Radiation Therapy (IMRT) + Bevacizumab (BV) For Locally or Regionally Advanced Nasopharyngeal CancerTerminatedIIHead and Neck [HN]Head and Neck
RTOG-0131A Phase II Trial of Pre-Irradiation and Concurrent Temozolomide in Patients With Newly Diagnosed Anaplastic Oligodendrogliomas and Mixed Anaplastic OligoastrocytomasTerminatedIIBrain [BN]CNS Metastatic Disease
RTOG-9813A Phase III (Phase I Closed) Randomized Study of Radiation Therapy and Temozolomide (IND #60,265) Versus Radiation Therapy and Nitrosourea for Anaplastic Astrocytoma and Mixed Anaplastic Oligoastrocytoma (Astrocytoma Dominant)TerminatedI/IIIBrain [BN]Other
RTOG-9802A Phase II Study of Observation in Favorable Low-Grade Glioma and Phase III Study of Radiation With or Without PCV Chemotherapy in Unfavorable Low-Grade GliomaTerminatedII/IIIBrain [BN]Other
RTOG-0938A Randomized Phase II Trial Of Hypofractionated Radiotherapy For Favorable Risk Prostate Cancer-RTOG CCOP StudyTerminatedIIGenitourinary [GU]Prostate
RTOG-0813Seamless Phase I/II Study of Stereotactic Lung Radiotherapy (SBRT) for Early Stage, Centrally Located, Non-Small Cell Lung Cancer (NSCLC) in Medically Inoperable PatientsTerminatedI/IILung [LU]Non-small Cell Lung Cancer
RTOG-0912A Randomized Phase II Study of Concurrent Intensity Modulated Radiation Therapy (IMRT), Paclitaxel and Pazopanib (NSC 737754)/Placebo, for The Treatment of Anaplastic Thyroid CancerTerminatedIIHead and Neck [HN]Head and Neck
RTOG-0415A Phase III Randomized Study of Hypofractionated 3DCRT/IMRT versus Conventionally Fractionated 3DCRT/IMRT in Patients Treated for Favorable-Risk Prostate CancerTerminatedIIIGenitourinary [GU]Prostate
RTOG-0521A Phase III Protocol of Androgen Suppression (AS) and 3DCRT/IMRT Vs. AS and 3DCRT/IMRT Followed by Chemotherapy with Docetaxel and Prednisone for Localized, High-Risk Prostate CancerTerminatedIIIGenitourinary [GU]Prostate
RTOG-0524A Phase I/II Trial of a Combination of Paclitaxel and Trastuzumab With Daily Irradiation or Paclitaxel Alone With Daily Irradiation Following Transurethral Surgery for Non-Cystectomy Candidates With Muscle-Invasive BladderTerminatedI/IIGenitourinary [GU]Bladder
RTOG-9910A Phase III Trial to Evaluate the Duration of Neoadjuvant Total Androgen Suppression (TAS) and Radiation Therapy (RT) in Intermediate-Risk Prostate CancerTerminatedIIIGenitourinary [GU]Prostate
RTOG-0837Randomized, Phase II, Double-Blind, Placebo-Controlled Trial of Conventional Chemoradiation and Adjuvant Temozolomide Plus Cediranib versus Conventional Chemoradiation and Adjuvant Temozolomide Plus Placebo in Patients with Newly Diagnosed GlioblastomaTerminatedIIBrain [BN]Other
RTOG-0631Phase II/III Study of Image-Guided Radiosurgery/SBRT for Localized Spine MetastasisTerminatedII/IIISymptom Management [CC]Other
RTOG-0617A Randomized Phase III Comparison of Standard- Dose (60 Gy) Versus Highdose (74 Gy) Conformal Radiotherapy with Concurrent and Consolidation Carboplatin/Paclitaxel +/- Cetuximab (IND #103444) in Patients with Stage IIIA/IIIB Non-Small Cell Lung CancerTerminatedIIILung [LU]Non-small Cell Lung Cancer
RTOG-0537A Phase II/III Study Comparing Acupuncture-like Transcutaneous Electrical Nerve Stimulation (ALTENS) Versus Pilocarpine in Treating Early Radiation-Induced XerostomiaTerminatedII/IIIHead and Neck [HN]Head and Neck
RTOG-1016Phase III Trial of Radiotherapy Plus Cetuximab Versus Chemoradiotherapy in HPV-Associated Oropharynx CancerClosed to AccrualIIIHead and Neck [HN]Head and Neck
RTOG-0126A Phase III Randomized Study of High Dose 3DCRT/IMRT versus Standard Dose 3DCRT/IMRT in Patients Treated for Localized Prostate CancerTerminatedIIIGenitourinary [GU]Prostate
RTOG-0526A Prospective Phase II Trial of Transperineal Ultrasound-Guided Brachytherapy for Locally Recurrent Prostate Adenocarcinoma Following External Beam RadiotherapyTerminatedIIGenitourinary [GU]Other
RTOG-0712A Phase II Randomized Study for Patients with Muscle-Invasive Bladder Cancer Evaluating Transurethral Surgery and Concomitant Chemoradiation by Either BID Irradiation plus 5-Fluorouracil and Cisplatin or QD Irradiation plus Gemcitabine Followed by Selective Bladder Preservation and Gemcitabine/Cisplatin Adjuvant ChemotherapyTerminatedIIGenitourinary [GU]Bladder
RTOG-0424A Phase II Study of a Temozolomide-Based Chemoradiotherapy Regimen for High Risk Low-Grade GliomasTerminatedIIBrain [BN]Lower Grade Glioma
RTOG-0539Phase II Trial of Observation for Low-Risk Meningiomas and of Radiotherapy for Intermediate- and High-Risk MeningiomasTerminatedIIBrain [BN]Other
RTOG-0913Phase I/II Trial of Concurrent RAD001 (Everolimus) With Temozolomide/Radiation Followed by Adjuvant RAD001/Temozolomide in Newly Diagnosed GlioblastomaTerminatedI/IIBrain [BN]Other
RTOG-1014A Phase II Study of Repeat Breast Preserving Surgery and 3D-Conformal Partial Breast Re-Irradiation (PBRI) for Local Recurrence of Breast CarcinomaTerminatedIIBreast [BR]Breast
RTOG-1205Randomized Phase II Trial of Concurrent Bevacizumab and Re-Irradiation Versus Bevacizumab Alone as Treatment for Recurrent GlioblastomaTerminatedIIBrain [BN]Other
RTOG-0436A Phase III Trial Evaluating the Addition of Cetuximab to Paclitaxel, Cisplatin, and Radiation for Patients With Esophageal Cancer Who Are Treated Without SurgeryTerminatedIIIGastrointestinal [GI]Esophageal
RTOG-1010A Phase III Trial Evaluating the Addition of Trastuzumab to Trimodality Treatment of Her2-Overexpressing Esophageal AdenocarcinomaTerminatedIIIGastrointestinal [GI]Esophageal
RTOG-9804Phase III Trial of Observation +/- Tamoxifen vs. RT +/- Tamoxifen for Good Risk Ductal Carcinoma In Situ (DCIS) of the Female BreastTerminatedIIIBreast [BR]Breast
RTOG-1005A Phase III Trial Of Accelerated Whole Breast Irradiation With Hypofractionation Plus Concurrent Boost Versus Standard Whole Breast Irradiation Plus Sequential Boost For Early-Stage Breast Cancer Closed to AccrualIIIBreast [BR]Breast
GOG-0263Randomized Phase III Clinical Trial of Adjuvant Radiation Versus Chemoradiation in Intermediate Risk, Stage I/IIA, Cervical Cancer Treated with Initial Radical Hysterectomy and Pelvic Lymphdenectomy.Closed to AccrualIIIGynecologic [GY]Cervix
NSABP B-47A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women with Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast CancerCompleteIIIBreast [BR]Breast
NRG-GI004/SWOG-S1610Colorectal Cancer Metastatic dMMR/MSI-H Immuno-therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab/Atezolizumab Combination Versus Single Agent Atezolizumab in the First-line Treatment of Patients With Deficient DNA Mismatch Repair (dMMR)/Microsatellite Instability-high (MSI-H) Metastatic Colorectal CancerOpen to AccrualIIIGastrointestinal [GI]Colorectal
GOG-0281A Randomized Phase II/III Study to Assess the Efficacy of Trametinib (GSK 1120212) in Patients with Recurrent or Progressive Low-Grade Serous Ovarian Cancer or Peritoneal CancerClosed to AccrualII/IIIGynecologic [GY]Ovarian
GOG-9928A Phase I study of the safety of intraperitoneal EGEN-001 (IL-12 plasmid formulated with PEG-PEI-Cholesterol lipopolymer) administered in combination with pegylated liposomal doxorubicin (PLD) in recurrent ovarian cancer patients. The purpose of this studtermine the safety of EGEN-001 IP plus PLD treatment in platinum-recurrent ovarian cancer patients.TerminatedIGynecologic [GY]Ovarian
GOG-9924A Phase I Pharmacokinetic Study of Intraperitoneal CTEP-Supplied Agent Bortezomib (PS-341, NSC 681239, IND# 58443) and Carboplatin (NSC# 241240)in Patients with Persistent or Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal CancerTerminatedIGynecologic [GY]Ovarian
GOG-0280A Phase II Eval of the Poly(ADP-Ribose)Polymerase (PARP)-1 and -2 Inhibitor Veliparib (ABT-888)(NSC #737644) in the tx of Persistent or Recurrent Ovarian, Fallopian Tube or Primary Peritoneal Ca in Patients who carry a germline BRCA 1 or 2 Mutation  TerminatedIIGynecologic [GY]Ovarian
RTOG-0920A Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally-Advanced Resected Head and Neck CancerClosed to AccrualIIIHead and Neck [HN]Head and Neck
NRG-BR001A Phase 1 Study of Stereotactic Body Radiotherapy (SBRT) for the Treatment of Multiple MetastasesTerminatedIBreast [BR]Breast
NRG-CC001A Randomized Phase III Trial of Memantine and Whole-Brain Radiotherapy With or Without Hippocampal Avoidance in Patients With Brain MetastasesTerminatedIIISymptom Management [CC]Other
NSABP NCIC CTG MA.32.FBiobehavioral Mechanisms of Fatigue in Patients Treated on NCIC CTG MA.32: A Phase III Randomized Trial of Metformin Versus Placebo on Recurrence and Survival in Early Stage Breast CancerCompleteIIIBreast [BR]Breast
NSABP B-52A Randomized Phase III Trial Evaluating Pathologic Complete Response Rates in Patients with Hormone Receptor-Positive, HER2-Positive, Large Operable and Locally Advanced Breast Cancer Treated with Neoadjuvant Therapy of Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab (TCHP) With or Without Estrogen DeprivationCompleteIIIBreast [BR]Breast
NSABP B-51 RTOG 1304A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant ChemotherapyClosed to AccrualIIIBreast [BR]Breast
NSABP B-49A Phase III Clinical Trial Comparing the Combination of Docetaxel Plus Cyclophosphamide to Anthracycline-Based Chemotherapy Regimens for Women with Node-Positive or High-Risk Node-Negative, HER2-Negative Breast CancerClosed to AccrualIIIBreast [BR]Breast
NSABP B-43A Phase III Clinical Trial Comparing Trastuzumab Given Concurrently with Radiation Therapy and Radiation Therapy Alone for Women with HER2-Positive Ductal Carcinoma In Situ Resected by LumpectomyClosed to AccrualIIIBreast [BR]Breast
NSABP B-42A Clinical Trial to Determine the Efficacy of Five Years of Letrozole Compared to Placebo in Patients Completing Five Years of Hormonal Therapy Consisting of an Aromatase Inhibitor (AI) or Tamoxifen Followed by an AI in Prolonging Disease-Free Survival in Postmenopausal Women with Hormone Receptor Positive Breast CancerClosed to Accrual & TreatmentIIIBreast [BR]Breast
NRG-BR003A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast CancerClosed to AccrualIIIBreast [BR]Breast
NRG-GY011A Randomized Surgical Window Pilot Investigation of the Relationship of Short Term Medroxyprogesterone Acetate (NSC #26386) Compared to Medroxyprogesterone Acetate Plus Entinostat (NSC #706995) on the Morphologic, Biochemical, and Molecular Changes in Primary Endometrioid Adenocarcinoma of the Uterine CorpusTerminatedIGynecologic [GY]Uterine Corpus
NRG-HN002A Randomized Phase II Trial for Patients with p16 Positive, Non-Smoking Associated, Locoregionally Advanced Oropharyngeal CancerClosed to AccrualIIHead and Neck [HN]Head and Neck
GOG-0286BA Randomized Phase II/III Study of Paclitaxel/Carboplatin/Metformin (NSC#91485) Versus Paclitaxel/Carboplatin/Placebo as Initial Therapy for Measurable Stage III or IVA, Stage IVB, or Recurrent Endometrial CancerClosed to AccrualII/IIIGynecologic [GY]Uterine Corpus
RTOG-1008A Randomized Phase II/Phase III Study of Adjuvant Concurrent Radiation and Chemotherapy versus Radiation Alone in Resected High-Risk Malignant Salivary Gland TumorsClosed to Accrual & TreatmentII/IIIHead and Neck [HN]Head and Neck
RTOG-0839Randomized Phase II Study of Pre-Operative Chemoradiotherapy +/- Panitumumab (IND #110152) Followed By Consolidation Chemotherapy In Potentially Operable Locally Advanced (Stage IIIA, N2+) Non-Small Cell Lung CancerTerminatedIILung [LU]Non-small Cell Lung Cancer